<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> (AZA) is the current treatment for patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, but resistance is a common feature of AZA-treated patients </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the mechanisms associated with AZA resistance in vitro, we generated AZA-resistant SKM1 myeloid cells, called hereafter AZA-R </plain></SENT>
<SENT sid="2" pm="."><plain>AZA-R cells exhibit impaired <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane permeabilization and caspase activation in response to AZA compared to their AZA-sensitive (AZA-S) counterpart </plain></SENT>
<SENT sid="3" pm="."><plain>AZA induced LC3-II accumulation and cathepsin B activity in AZA-S cells, two hallmarks of autophagy </plain></SENT>
<SENT sid="4" pm="."><plain>AZA-R cells displayed increased basal autophagy but are resistant to AZA-mediated autophagy </plain></SENT>
<SENT sid="5" pm="."><plain>Inhibition of autophagy using LC3 siRNA revealed that autophagy is protective in AZA-S cells and AZA-R cells in basal conditions </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, AZA-R cells exhibited impaired autophagy in response to AZA </plain></SENT>
<SENT sid="7" pm="."><plain>Collectively, our findings indicate that AZA promotes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and autophagy in SKM1 cells, and that AZA-R cells are resistant to both <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and autophagy induced by AZA </plain></SENT>
</text></document>